Top insider buys and sells disclosed on Friday
On Friday, insiders made notable trades in US-listed companies. Baker Bros. bought $35M in Madrigal Pharmaceuticals (MDGL) shares, Kinder Morgan's (KMI) CEO bought $15M in stock, and Kennametal's (KMT) CEO acquired $165k in shares. Meanwhile, Royal Caribbean's (RCL) director sold $82M in stock, and Gilead's (GILD) CEO sold $19.7M in shares. InvestingPro analysis suggests some stocks are undervalued or overvalued.
How this was made
The 30-second read
Why it matters
While insider trades provide clues, the overall market impact is likely muted given the routine nature of most transactions.
Market read
Insider activity may influence short‑term price moves for the listed tickers but does not constitute a market‑wide catalyst.
What to watch
Many purchases are at low price levels; market may already price in insider confidence.
Background
The article aggregates recent Form 4 filings for US‑listed companies, highlighting notable insider purchases and sales.
Ticker impact
Director Julian C. Baker and affiliates bought 91,806 shares for $35.0M, signaling confidence amid a 31% YTD decline.
likely modest upside as market prices in insider confidence
Large purchase at near 52‑week low suggests belief the stock is undervalued.
Executive Chairman Richard D. Kinder purchased 500,000 shares for $15.0M, adding to his holdings.
likely slight upward bias as a major insider adds a sizable block
Buy by a 10% owner signals confidence despite recent 11% weekly dip.
President James C. Baker bought 25,000 shares for $331,085.
potential modest lift
Small purchase relative to market cap; limited impact.
CEO Sanjay Chowbey acquired 7,000 shares for $165,368.
possible slight upside
Insider buy at near 52‑week low, but size is modest.
Director Wajid Ali bought 10,000 shares for $631,541.
likely minimal upward pressure
Purchase size modest relative to recent 25% weekly decline.
Director Arne Alexander Wilhelmsen sold 240,000 shares for $82.1M.
likely slight sell pressure
Large insider sale may signal concerns despite recent price gains.
CEO Mark Barrocas sold 113,156 shares for $25.0M.
potential modest downside
Significant insider sell near 52‑week high could be viewed as profit taking.
CEO Daniel O’Day sold ~112,429 shares for $19.7M under a 10b5‑1 plan, while also exercising options worth $8.1M.
likely slight downward bias
Large net sale near 52‑week high suggests reduced confidence.
Market effects
Insider activity across healthcare, energy, industrials may hint at sector confidence trends.
US market sentiment may be modestly influenced by high‑profile insider buys in energy and biotech.
Limited; primarily US‑focused insider transactions.
Counterpoint
Large insider sells could signal underlying concerns despite recent price gains.
Key entities
- DirectorJulian C. Baker
Director of Madrigal Pharmaceuticals, insider buyer.
- Executive ChairmanRichard D. Kinder
Kinder Morgan insider buyer.
- DirectorArne Alexander Wilhelmsen
Royal Caribbean insider seller.



